Cancer Therapy News and Research

RSS

Advisers to Presidential candidates discuss positions on reimportation, generics, biotechnology medications

Democratic presidential nominee Sen. Barack Obama (Ill.) and Republican presidential nominee Sen. John McCain (Ariz.) have begun "reviewing their support" for prescription drug reimportation in response to recent cases of contaminated medications and other products from other nations, advisers to the candidates said on Thursday during the annual conference of the Generic Pharmaceutical Association in Washington, D.C., Reuters/Boston Globe reports.

22 Sep 2008

Discovery of promising new chemotherapy target for a deadly form of leukemia

Cancer researchers at the Stanford University School of Medicine have discovered a promising new chemotherapy target for a deadly form of leukemia. Their discovery hinges on a novel "double agent" role for a molecular signal that regulates cell growth.

17 Sep 2008

Benefits of combined treatments against cancer

In cancer therapy, the best results are often achieved by combining treatments such as chemotherapy, radiotherapy and surgery. This multidisciplinary approach is the focus of special symposia at the meetings of the European Society for Medical Oncology (ESMO) and the European Society for Therapeutic Radiology (ESTRO) taking place in Sweden this month.

16 Sep 2008

Pathways to clinical goals speeds cancer therapy approval

Although cancer remains a leading cause of death in America, it can take up to 12 years to bring a new anti-cancer agent before the FDA and the success rate for approval is only five to 10 percent. That means many research hours and dollars are wasted chasing avenues that will not bring fruit.

15 Sep 2008

Significant benefits in non-small-cell lung cancer from customizing erlotinib treatment

Lung cancer patients whose tumors carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report.

15 Sep 2008

Surveillance mammography after treatment for primary breast cancer

The National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has commissioned a new study to identify the most effective and efficient surveillance methods for women who have received treatment for primary breast cancer.

14 Sep 2008

Atomic structure of the mammalian "fatty acid factory" determined

Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders. Now researchers at ETH Zurich have determined the atomic structure of a mammalian fatty acid synthase. Their results have just been published in Science magazine.

7 Sep 2008

Trastuzumab-DM1 - a 'smart bomb' for breast cancer treatment

Sarah Cannon Research Institute (SCRI) investigators have found that "smart bomb" therapies are effective in treating breast cancer patients while minimizing side effects.

7 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Height linked to risk of prostate cancer

A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say Bristol researchers who conducted their own study on the connection and also reviewed 58 published studies.

3 Sep 2008

A man's height linked to prostate cancer development and progression

A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies.

3 Sep 2008

Anadis Ltd's clinical trial against mucositis approved in Israel

Anadis Ltd., an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH).

3 Sep 2008

Algeta reports positive phase II data on pain palliation with Alpharadin

Algeta ASA today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose.

28 Aug 2008

Many people mistaken about the causes of cancer

A large international survey for the International Union Against Cancer (UICC) has revealed that many people have misconceptions about what causes cancer.

27 Aug 2008

Global survey highlights need for cancer prevention campaigns to correct misbeliefs

Many people hold mistaken beliefs about what causes cancer, tending to inflate the threat from environmental factors that have relatively little impact while minimizing the hazards of behaviours well established as cancer risk factors, according to the first global survey on the topic.

26 Aug 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

ICMT enzyme shows potential as target in treating blood cancer

A discovery by a research team with the Sahlgrenska Academy at Gothenburg University in Sweden may lead to new treatments for blood cancer and other diseases. By stopping the production of a specific enzyme, ICMT, researchers were able to alleviate disease symptoms in mice with blood cancer.

21 Aug 2008

By amplifying cell death signals, scientists make precancerous cells self-destruct

When a cell begins to multiply in a dangerously abnormal way, a series of death signals trigger it to self-destruct before it turns cancerous. Now, in research to appear in the August 15 issue of Genes & Development, Rockefeller University scientists have figured out a way in mice to amplify the signals that tell these precancerous cells to die. The trick: Inactivating a protein that normally helps cells to avoid self-destruction.

17 Aug 2008

Rituximab significantly reduces kidney injury in membranous nephropathy

The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a study appearing in the November 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN).

6 Aug 2008

Discovery of vital key to cancer

University of Manchester scientists have uncovered the 3D structure of Mps1 - a protein that regulates the number of chromosomes during cell division and thus has an essential role in the prevention of cancer - which will lead to the design of safer and more effective therapies.

From The University of Manchester 6 Aug 2008